Subchronic Oral Toxicity Testing in Rats and Mice: Study Design, Endpoints, and Regulatory Applicati

The subchronic oral toxicity test in rats and mice is a cornerstone of repeated-dose toxicology, evaluating the adverse effects of a test substance administered orally over 90 days to determine the no-observed-adverse-effect level (NOAEL) and identify target organs. Conducted in accordance with internationally recognized guidelines such as OECD Test Guideline 408, GB/T 21763, and GB 15193.26, this study provides critical data for the safety assessment of chemicals, pesticides, food additives, and consumer products. This article presents a comprehensive technical overview of the study design, tested sample categories, measured endpoints, and practical applications of subchronic oral toxicity testing in rodent models.

Technical Overview

The subchronic oral toxicity study is a laboratory animal experiment in which a test substance is administered to rats or mice by the oral route on a daily basis over an extended period, typically 90 days. The study spans approximately 10 percent of the lifespan of a rodent, which corresponds to a meaningful fraction of human exposure duration. The primary objective is to characterize the dose-response relationship of toxic effects, identify target organs and tissues, and derive key reference values such as the no-observed-adverse-effect level (NOAEL), the no-observed-effect level (NOEL), and the lowest-observed-adverse-effect level (LOAEL).

Subchronic testing occupies a central position in the tiered approach to toxicity evaluation. It bridges the gap between short-term acute studies and long-term chronic or carcinogenicity studies. The results inform dose selection for subsequent reproductive, developmental, and chronic toxicity studies and support the derivation of acceptable daily intake (ADI) values and occupational exposure limits.

The study is performed in compliance with Good Laboratory Practice (GLP) principles and internationally harmonized protocols, including OECD Test Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents), OECD Test Guideline 407 (28-Day Repeated Dose Oral Toxicity), GB/T 21763 for chemical substances, GB 15193.26 for food safety evaluation, and the United States EPA OPPTS 870.3100 guideline.

Testing Samples

A wide range of substances requiring safety characterization undergo subchronic oral toxicity evaluation in rats and mice. Typical sample categories include the following:

Industrial and Fine Chemicals

New and existing chemical substances subject to registration under chemical control regulations, including solvents, intermediates, surfactants, catalysts, dyestuffs, and nanomaterials. These studies support regulatory dossiers for chemical inventories and notification schemes worldwide.

Pesticides and Agrochemicals

Active ingredients and formulations of insecticides, herbicides, fungicides, and plant growth regulators. Subchronic studies are mandatory data requirements for pesticide registration and residue risk assessment.

Food-Related Substances

Food additives, novel food ingredients, health foods and functional food products, food processing aids, genetically modified food-derived materials, and substances migrating from food contact materials and packaging.

Pharmaceutical and Biotechnology Products

Small molecule drug candidates, excipients, botanical extracts, and biologics intended for repeated oral administration. Repeat-dose toxicity studies are fundamental to enabling clinical trials.

Cosmetics and Consumer Product Ingredients

Although many cosmetic safety evaluations rely on alternative methods, ingredients with potential systemic exposure through ingestion or absorption are frequently assessed using rodent subchronic studies where required by regulation.

Environmental and Water Treatment Chemicals

Disinfectants, coagulants, and treatment agents with the potential for residual presence in drinking water or the environment.

Testing Items

The subchronic oral toxicity study integrates in-life observations, functional tests, clinical pathology, and post-mortem examinations. The principal endpoints are summarized below:

• Clinical observations: daily assessment of general health, behavior, skin, fur, mucous membranes, secretion and excretion abnormalities, and signs of toxicity, including morbidity and mortality checks.
• Body weight and food consumption: weekly measurement of body weight, food intake, and where relevant water consumption, to detect treatment-related effects on growth and nutritional status.
• Functional observational battery: detailed neurological and behavioral assessments including sensory reactivity, grip strength, motor activity, and autonomic function, typically performed in the final weeks of dosing.
• Ophthalmological examination: inspection of the eyes using an ophthalmoscope or slit lamp before dosing and near study termination.
• Hematology: erythrocyte count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, total and differential leukocyte counts, platelet count, and coagulation parameters such as prothrombin time and activated partial thromboplastin time.
• Clinical chemistry: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, blood urea nitrogen, creatinine, glucose, total protein, albumin, globulin, cholesterol, triglycerides, and electrolytes including sodium, potassium, and chloride.
• Urinalysis: urine volume, pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and sediment microscopy.
• Terminal body and organ weights: body weight at scheduled necropsy and weights of the liver, kidneys, adrenals, spleen, brain, heart, thymus, thyroid, and reproductive organs, with calculation of organ-to-body-weight ratios.
• Gross necropsy: thorough macroscopic examination of all external surfaces, orifices, cranial cavity, and thoracic and abdominal cavities and their contents.
• Histopathology: microscopic examination of a comprehensive list of organs and tissues from control and high-dose animals, extended to lower-dose groups when treatment-related findings are present.
• Reproductive organ assessment: histopathology of testes, epididymides, ovaries, and uterus, with optional sperm parameters including motility, count, and morphology.

Testing Methods

Animal Selection and Husbandry

Rodent species are specified by the relevant guidelines, most commonly the rat (Sprague-Dawley or Wistar strains) and, where a second species is justified, the mouse (ICR, KM, or CD-1 strains). Healthy young adult animals, typically 6 to 8 weeks old at study initiation, are acclimatized for at least 5 to 7 days under controlled environmental conditions. Temperature, relative humidity, ventilation, lighting cycles, and cage density are maintained within ranges specified by the applicable guideline, and animals are randomized into groups to minimize bias. Standard test designs use at least 10 animals per sex per group for 90-day studies.

Study Design and Dose Groups

The classic design comprises a vehicle control group and at least three treated groups administered the low, intermediate, and high dose of the test substance. The high dose is expected to produce toxic effects without excessive mortality or severe suffering, the low dose should ideally be a no-observed-effect level, and the intermediate dose should produce gradable toxicity. The dose interval is generally spaced at two- to four-fold increments. A satellite or recovery group may be added to evaluate the reversibility of observed effects after a treatment-free period.

Route and Method of Administration

The test substance is administered orally by one of the following approaches, selected to mimic expected human exposure:

• Oral gavage: precise dosing via a stomach tube at a defined volume, typically not exceeding 10 mL/kg body weight for aqueous vehicles or 5 mL/kg for oils, administered at consistent times each day.
• Dietary admixture: incorporation of the test substance into feed at concentrations adjusted to maintain constant dose in mg/kg body weight per day.
• Drinking water: dissolution of the test substance in the drinking water supply, suitable for water-soluble materials.
• Capsule administration: used occasionally for special test articles requiring accurate delivery.

The dosing preparation is analyzed for concentration, homogeneity, and stability to verify actual exposure levels throughout the study.

Dose Selection and Preliminary Studies

Dose levels are established using data from acute oral toxicity studies, 14-day or 28-day range-finding studies, or structure-based read-across evidence. Mortality, clinical signs, body weight change, and any available mechanistic information are considered to set doses that satisfy regulatory expectations for hazard characterization.

Data Interpretation and Reporting

All collected data undergo statistical evaluation, with appropriate methods such as ANOVA followed by pairwise comparisons, Bartlett's test for variance homogeneity, and non-parametric alternatives where assumptions are not met. Findings are interpreted jointly to identify target organs, establish dose-response relationships, and determine the NOAEL. The final report presents individual and group data, historical control ranges, necropsy and histopathology findings, and a scientific conclusion addressing adverse effects and their biological significance.

Applications

Subchronic oral toxicity data in rats and mice serve multiple regulatory and commercial purposes:

• Chemical registration and notification: fulfilling data requirements for new chemical substance notifications and existing chemical evaluations under national and regional chemical regulations.
• Pesticide registration: supporting the establishment of ADI values, acute reference doses, and risk assessments for active ingredients and crop protection products.
• Food safety assessment: forming part of the toxicological dossier required for food additives, novel foods, health foods, and food ingredients under the applicable national food safety standards.
• Pharmaceutical development: enabling first-in-human clinical trials by characterizing repeated-dose toxicity, target organs, and safe starting doses.
• Occupational and consumer safety: deriving acceptable exposure levels for workplaces, product safety documentation, and hazard classification under the Globally Harmonized System (GHS).
• Environmental risk assessment: supplying dose-response data for ecological and human health risk models.

Accredited third-party laboratories operating under GLP certification perform these studies for manufacturers, importers, and regulatory submitters, ensuring that the generated data meet the quality and traceability requirements of authorities across different jurisdictions.

FAQ

What is the difference between a 28-day and a 90-day oral toxicity study?

The 28-day repeated-dose study, described in OECD Test Guideline 407, is a shorter-range finding study that screens for gross toxicity and supports dose setting. The 90-day subchronic study, described in OECD Test Guideline 408, provides more comprehensive characterization of target organ toxicity, hematological and clinical chemistry effects, and histopathological lesions, and delivers more robust NOAEL values for risk assessment.

Should the study be performed in rats or mice?

The rat is the standard species for subchronic oral toxicity testing due to its size, extensive historical control data, and suitability for clinical pathology sampling. Mice are used when a second rodent species is required, when tissue requirements are limited, or when specific strains relevant to the mode of action are needed. The selection is ultimately dictated by the applicable regulatory guideline.

How are dose levels determined?

Dose levels are selected based on acute toxicity data and range-finding studies. The high dose should induce observable toxic effects without unacceptable mortality, the low dose should produce no adverse effects, and the mid dose should ideally reveal a graded response. Regulatory guidelines typically require dose spacing of two- to four-fold between groups.

What is a NOAEL and why is it important?

The NOAEL is the highest dose at which no biologically significant adverse effects are observed compared with the control group. It is the principal starting point for calculating acceptable daily intake values, reference doses, and exposure limits used in human health risk assessment and product safety regulation.

How long does a subchronic oral toxicity study take?

The in-life dosing phase lasts 90 days, and with acclimatization, necropsy, histopathology, and report finalization, the total study duration is typically four to six months. Recovery groups extend the timeline by an additional two to four weeks.

Is GLP compliance mandatory for these studies?

For regulatory submissions, most authorities require that subchronic toxicity studies be conducted in accordance with GLP principles covering study planning, conduct, documentation, archiving, and quality assurance. GLP compliance ensures data integrity and international acceptance of the results.

What sample quantity is required for testing?

The required amount depends on the dose levels, number of animals, and dosing duration. As a practical estimate, laboratories calculate the total consumption from the maximum dose, animal body weights, and dosing period, then add a surplus for formulation analysis, stability testing, and potential repeat preparations. Sponsors should confirm the specific quantity with the testing laboratory before study initiation.